Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FB CD22 (Clusters of Differentiation 22) inhibitors
L01FB01 Inotuzumab ozogamicin
D08933 Inotuzumab ozogamicin (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Inotuzumab Ozogamicin
D08933 Inotuzumab ozogamicin (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
423 Antibiotics
4239 Others
D08933 Inotuzumab ozogamicin (USAN/INN); Inotuzumab ozogamicin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
SIGLEC family
CD22 (SIGLEC2)
D08933 Inotuzumab ozogamicin (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08933
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08933
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08933
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08933
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D08933
